Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Dermatology

  Free Subscription


Articles published in Cancer Lett

Retrieve available abstracts of 165 articles:
HTML format



Single Articles


    June 2021
  1. SINGHAL SS, Srivastava S, Mirzapoiazova T, Horne D, et al
    Targeting the mercapturic acid pathway for the treatment of melanoma.
    Cancer Lett. 2021;518:10-22.
    PubMed     Abstract available


    April 2021
  2. COPPO R, Orso F, Virga F, Dalmasso A, et al
    ESDN inhibits melanoma progression by blocking E-selectin expression in endothelial cells via STAT3.
    Cancer Lett. 2021;510:13-23.
    PubMed     Abstract available


    March 2021
  3. GRILLO E, Corsini M, Ravelli C, Zammataro L, et al
    Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence.
    Cancer Lett. 2021;507:80-88.
    PubMed     Abstract available


  4. MA Y, Wang L, He F, Yang J, et al
    LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction.
    Cancer Lett. 2021 Mar 3. pii: S0304-3835(21)00101.
    PubMed     Abstract available


    February 2021
  5. DANG N, Lin Y, Waer M, Sprangers B, et al
    Immunization with alloantibodies-covered melanoma cells induces regional antitumor effects that become systemic when combined with 5-FU treatment.
    Cancer Lett. 2021;503:151-162.
    PubMed     Abstract available


    January 2021
  6. VAN DE VELDE M, Ebroin M, Durre T, Joiret M, et al
    Tumor exposed-lymphatic endothelial cells promote primary tumor growth via IL6.
    Cancer Lett. 2021;497:154-164.
    PubMed     Abstract available


  7. WU PK, Hong SK, Park JI
    Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf(V600E) melanoma cells.
    Cancer Lett. 2021 Jan 10. pii: S0304-3835(21)00007.
    PubMed     Abstract available


    December 2020
  8. BOTELHO DE SOUZA LE, Ferreira FU, Thome CH, Brand H, et al
    Human and mouse melanoma cells recapitulate an EMT-like program in response to mesenchymal stromal cells secretome.
    Cancer Lett. 2020 Dec 28. pii: S0304-3835(20)30701.
    PubMed     Abstract available


  9. SHI Y, Zhang Y, Ran F, Liu J, et al
    Let-7a-5p inhibits triple-negative breast tumor growth and metastasis through GLUT12-mediated warburg effect.
    Cancer Lett. 2020;495:53-65.
    PubMed     Abstract available


  10. ZHANG T, Wu B, Akakuru OU, Yao C, et al
    Hsp90 inhibitor-loaded IR780 micelles for mitochondria-targeted mild-temperature photothermal therapy in xenograft models of human breast cancer.
    Cancer Lett. 2020;500:41-50.
    PubMed     Abstract available


  11. MAVINGIRE N, Campbell P, Wooten J, Aja J, et al
    Cancer stem cells: Culprits in endocrine resistance and racial disparities in breast cancer outcomes.
    Cancer Lett. 2020 Dec 9. pii: S0304-3835(20)30664.
    PubMed     Abstract available


  12. KIM SJ, Saeidi S, Cho NC, Kim SH, et al
    Interaction of Nrf2 with dimeric STAT3 induces IL-23 expression: Implications for breast cancer progression.
    Cancer Lett. 2020 Dec 2. pii: S0304-3835(20)30645.
    PubMed     Abstract available


    November 2020
  13. HARTMAN ML, Gajos-Michniewicz A, Talaj JA, Mielczarek-Lewandowska A, et al
    BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF(V600E) melanoma cells.
    Cancer Lett. 2020 Nov 28. pii: S0304-3835(20)30635.
    PubMed     Abstract available


  14. KIM G, Bhattarai PY, Lim SC, Kim JY, et al
    PIN1 facilitates ubiquitin-mediated degradation of serine/threonine kinase 3 and promotes melanoma development via TAZ activation.
    Cancer Lett. 2020 Nov 27. pii: S0304-3835(20)30631.
    PubMed     Abstract available


  15. WANG YY, Hung AC, Lo S, Yuan SF, et al
    Adipocytokines visfatin and resistin in breast cancer: Clinical relevance, biological mechanisms, and therapeutic potential.
    Cancer Lett. 2020 Nov 2. pii: S0304-3835(20)30580.
    PubMed     Abstract available


  16. ZENG J, Li G, Xia Y, Wang F, et al
    miR-204/COX5A axis contributes to invasion and chemotherapy resistance in estrogen receptor-positive breast cancers.
    Cancer Lett. 2020;492:185-196.
    PubMed     Abstract available


    October 2020
  17. PHAM K, Huynh D, Le L, Delitto D, et al
    E-cigarette promotes breast carcinoma progression and lung metastasis: Macrophage-tumor cells crosstalk and the role of CCL5 and VCAM-1.
    Cancer Lett. 2020;491:132-145.
    PubMed     Abstract available


  18. BAI X, Ni J, Beretov J, Graham P, et al
    Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
    Cancer Lett. 2020;497:100-111.
    PubMed     Abstract available


  19. ZHANG N, Sun P, Xu Y, Li H, et al
    The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERalpha to inhibit the growth of breast cancer induced by oestrogen.
    Cancer Lett. 2020 Oct 15. pii: S0304-3835(20)30545.
    PubMed     Abstract available


  20. DUTTA I, Dieters-Castator D, Papatzimas JW, Medina A, et al
    ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to gammadelta T cell immunotherapy.
    Cancer Lett. 2020 Oct 9. pii: S0304-3835(20)30535.
    PubMed     Abstract available


    September 2020
  21. OH JH, Lee JY, Kim KH, Kim CY, et al
    Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer.
    Cancer Lett. 2020;495:145-155.
    PubMed     Abstract available


  22. LIU S, Zhang J, Fang S, Su X, et al
    Antitumor efficacy of oncolytic HSV-1 expressing cytosine deaminase is synergistically enhanced by DPD down-regulation and EMT inhibition in uveal melanoma xenograft.
    Cancer Lett. 2020 Sep 15. pii: S0304-3835(20)30475.
    PubMed     Abstract available


  23. LI Y, Zhang H, Li Q, Zou P, et al
    CDK12/13 inhibition induces immunogenic cell death and enhances anti-PD-1 anticancer activity in breast cancer.
    Cancer Lett. 2020 Sep 14. pii: S0304-3835(20)30473.
    PubMed     Abstract available


  24. SMALLEY H, Rowe JM, Nieto F, Zeledon J, et al
    Beta2 glycoprotein I-derived therapeutic peptides induce sFlt-1 secretion to reduce melanoma vascularity and growth.
    Cancer Lett. 2020 Sep 3. pii: S0304-3835(20)30453.
    PubMed     Abstract available


  25. RONG Y, Huang LX, Yi KZ, Chen H, et al
    Co-administration of sulforaphane and doxorubicin attenuates breast cancer growth by preventing the accumulation of myeloid-derived suppressor cells.
    Cancer Lett. 2020 Sep 3. pii: S0304-3835(20)30455.
    PubMed     Abstract available


    August 2020
  26. MA L, Wang L, Nelson AT, Han C, et al
    27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.
    Cancer Lett. 2020 Aug 27. pii: S0304-3835(20)30435.
    PubMed     Abstract available


  27. LOBO YA, Bonazza C, Batista FP, Castro RA, et al
    EcTI impairs survival and proliferation pathways in triple-negative breast cancer by modulating cell-glycosaminoglycans and inflammatory cytokines.
    Cancer Lett. 2020 Aug 22. pii: S0304-3835(20)30431.
    PubMed     Abstract available


  28. ZHAO CC, Zhan MN, Liu WT, Jiao Y, et al
    Combined LIM kinase 1 and p21-Activated kinase 4 inhibitor treatment exhibits potent preclinical antitumor efficacy in breast cancer.
    Cancer Lett. 2020 Aug 20. pii: S0304-3835(20)30419.
    PubMed     Abstract available


  29. XIE Y, Hu Y, Zhou N, Yao C, et al
    CAR T-cell therapy for triple-negative breast cancer: Where we are.
    Cancer Lett. 2020 Aug 11. pii: S0304-3835(20)30400.
    PubMed     Abstract available


  30. TEOH ST, Ogrodzinski MP, Lunt SY
    UDP-glucose 6-dehydrogenase knockout impairs migration and decreases in vivo metastatic ability of breast cancer cells.
    Cancer Lett. 2020 Aug 5. pii: S0304-3835(20)30388.
    PubMed     Abstract available


  31. REN J, Wang Y, Ware T, Iaria J, et al
    Reactivation of BMP signaling by suboptimal concentrations of MEK inhibitor and FK506 reduces organ-specific breast cancer metastasis.
    Cancer Lett. 2020 Aug 5. pii: S0304-3835(20)30398.
    PubMed     Abstract available


    July 2020
  32. NIETO-JIMENEZ C, Galan-Moya EM, Corrales-Sanchez V, Del Mar Noblejas-Lopez M, et al
    Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
    Cancer Lett. 2020 Jul 28. pii: S0304-3835(20)30350.
    PubMed     Abstract available


  33. RONG D, Wang C, Zhang X, Wei Y, et al
    A novel taxane, difluorovinyl-ortataxel, effectively overcomes paclitaxel-resistance in breast cancer cells.
    Cancer Lett. 2020 Jul 27. pii: S0304-3835(20)30355.
    PubMed     Abstract available


  34. HWANG HJ, Lee YR, Kang D, Lee HC, et al
    Endothelial cells under therapy-induced senescence secrete CXCL11, which increases aggressiveness of breast cancer cells.
    Cancer Lett. 2020 Jul 10. pii: S0304-3835(20)30349.
    PubMed     Abstract available


    June 2020
  35. HUANG B, Yip WK, Wei N, Luo KQ, et al
    Acetyltanshinone IIA is more potent than lapatinib in inhibiting cell growth and degrading HER2 protein in drug-resistant HER2-positive breast cancer cells.
    Cancer Lett. 2020 Jun 22. pii: S0304-3835(20)30340.
    PubMed     Abstract available


  36. AGGARWAL V, Miranda O, Johnston PA, Sant S, et al
    Three dimensional engineered models to study hypoxia biology in breast cancer.
    Cancer Lett. 2020 Jun 19. pii: S0304-3835(20)30292.
    PubMed     Abstract available


  37. BABAK MV, Zalutsky MR, Balyasnikova IV
    Heterogeneity and vascular permeability of breast cancer brain metastases.
    Cancer Lett. 2020 Jun 16. pii: S0304-3835(20)30342.
    PubMed     Abstract available


  38. WANG B, Mao JH, Wang BY, Wang LX, et al
    Exosomal miR-1910-3p promotes proliferation, metastasis, and autophagy of breast cancer cells by targeting MTMR3 and activating the NF-kappaB signaling pathway.
    Cancer Lett. 2020 Jun 9. pii: S0304-3835(20)30300.
    PubMed     Abstract available


    May 2020
  39. FERRER A, Roser CT, El-Far MH, Savanur VH, et al
    Hypoxia-mediated changes in bone marrow microenvironment in breast cancer dormancy.
    Cancer Lett. 2020 May 29. pii: S0304-3835(20)30288.
    PubMed     Abstract available


  40. BISHOP RT, Marino S, Carrasco G, Li B, et al
    Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis.
    Cancer Lett. 2020 May 28. pii: S0304-3835(20)30282.
    PubMed     Abstract available


  41. BARUA D, Gupta A, Gupta S
    Targeting the IRE1-XBP1 axis to overcome endocrine resistance in breast cancer: Opportunities and challenges.
    Cancer Lett. 2020 May 21. pii: S0304-3835(20)30283.
    PubMed     Abstract available


  42. HE Z, Khatib AM, Creemers JWM
    Loss of the proprotein convertase Furin in T cells represses mammary tumorigenesis in oncogene-driven triple negative breast cancer.
    Cancer Lett. 2020 May 7. pii: S0304-3835(20)30229.
    PubMed     Abstract available


    April 2020
  43. SZOOR A, Toth G, Zsebik B, Szabo V, et al
    Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies.
    Cancer Lett. 2020 Apr 11. pii: S0304-3835(20)30185.
    PubMed     Abstract available


  44. ULASOV I, Borovjagin A, Fares J, Yakushov S, et al
    MicroRNA 345 (miR345) regulates KISS1-E-cadherin functional interaction in breast cancer brain metastases.
    Cancer Lett. 2020;481:24-31.
    PubMed     Abstract available


    March 2020
  45. ANG L, Guo L, Wang J, Huang J, et al
    Oncolytic virotherapy armed with an engineered interfering lncRNA exhibits antitumor activity by blocking the epithelial mesenchymal transition in triple-negative breast cancer.
    Cancer Lett. 2020 Mar 18. pii: S0304-3835(20)30131.
    PubMed     Abstract available


  46. SHEN L, Kang L, Wang D, Xun J, et al
    Legumain-deficient macrophages promote senescence of tumor cells by sustaining JAK1/STAT1 activation.
    Cancer Lett. 2020;472:40-49.
    PubMed     Abstract available


    February 2020
  47. LI T, Zhang C, Zhao G, Zhang X, et al
    IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma.
    Cancer Lett. 2020 Feb 28. pii: S0304-3835(20)30105.
    PubMed     Abstract available


  48. BHUI K, Prasad S, George J, Shukla Y, et al
    Corrigendum to "Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NF-kappa B against skin tumor-initiation triggering mitochondrial death pathway" [Canc. Lett. (2009) 282(2) 167-76 doi:10.1016/j.canlet.2009.03.003].
    Cancer Lett. 2020 Feb 5. pii: S0304-3835(20)30025.
    PubMed    


  49. RIOS-LUCI C, Diaz-Rodriguez E, Gandullo-Sanchez L, Diaz-Gil L, et al
    Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms.
    Cancer Lett. 2020;470:161-169.
    PubMed     Abstract available


    January 2020
  50. DING J, Yao Y, Huang G, Wang X, et al
    Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
    Cancer Lett. 2020 Jan 29. pii: S0304-3835(20)30046.
    PubMed     Abstract available


  51. NAN X, Wang J, Cheng H, Yin Z, et al
    Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways.
    Cancer Lett. 2020;469:195-206.
    PubMed     Abstract available


  52. WU J, Yan J, Fang P, Zhou HB, et al
    Three-dimensional oxabicycloheptene sulfonate targets the homologous recombination and repair programmes through estrogen receptor alpha antagonism.
    Cancer Lett. 2020;469:78-88.
    PubMed     Abstract available


  53. FLORES-GUZMAN F, Utikal J, Umansky V
    Dormant tumor cells interact with memory CD8(+) T cells in RET transgenic mouse melanoma model.
    Cancer Lett. 2020 Jan 18. pii: S0304-3835(20)30024.
    PubMed     Abstract available


  54. GOH CY, Wyse C, Ho M, O'Beirne E, et al
    Exosomes in Triple Negative Breast Cancer: Garbage Disposals or Trojan Horses?
    Cancer Lett. 2020 Jan 2. pii: S0304-3835(19)30668.
    PubMed     Abstract available


  55. BAROK M, Le Joncour V, Martins A, Isola J, et al
    ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
    Cancer Lett. 2020 Jan 2. pii: S0304-3835(19)30659.
    PubMed     Abstract available


    December 2019
  56. SAND A, Piacsek M, Donohoe DL, Duffin AT, et al
    WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer.
    Cancer Lett. 2019;472:119-131.
    PubMed     Abstract available


  57. SI P, Shi J, Zhang P, Wang C, et al
    MUC-1 recognition-based activated drug nanoplatform improves doxorubicin chemotherapy in breast cancer.
    Cancer Lett. 2019 Dec 16. pii: S0304-3835(19)30625.
    PubMed     Abstract available


    November 2019
  58. PINA MJ, Girotti A, Serrano S, Munoz R, et al
    A Double Safety Lock Tumor-Specific Device for Suicide Gene Therapy in Breast Cancer.
    Cancer Lett. 2019 Nov 29. pii: S0304-3835(19)30586.
    PubMed     Abstract available


  59. PAN T, Zhou D, Shi Z, Qiu Y, et al
    Centromere Protein U (CENPU) enhances angiogenesis in triple-negative breast cancer by inhibiting ubiquitin-proteasomal degradation of COX-2.
    Cancer Lett. 2019 Nov 6. pii: S0304-3835(19)30558.
    PubMed     Abstract available


    October 2019
  60. KIM JE, Kim BG, Jang Y, Kang S, et al
    The stromal loss of miR-4516 promotes the FOSL1-dependent proliferation and malignancy of triple negative breast cancer.
    Cancer Lett. 2019 Oct 28. pii: S0304-3835(19)30542.
    PubMed     Abstract available


    September 2019
  61. ZOU H, Chen H, Zhou Z, Wan Y, et al
    ATXN3 promotes breast cancer metastasis by deubiquitinating KLF4.
    Cancer Lett. 2019 Sep 26. pii: S0304-3835(19)30484.
    PubMed     Abstract available


  62. VOSHTANI R, Song M, Wang H, Li X, et al
    Progranulin promotes melanoma progression by inhibiting natural killer cell recruitment to the tumor microenvironment.
    Cancer Lett. 2019;465:24-35.
    PubMed     Abstract available


    August 2019
  63. WANG S, Oh DY, Leventaki V, Drakos E, et al
    MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer.
    Cancer Lett. 2019;465:12-23.
    PubMed     Abstract available


  64. ANDRIEU GP, Shafran JS, Smith CL, Belkina AC, et al
    BET Protein Targeting Suppresses the PD-1/PD-L1 Pathway in Triple-Negative Breast Cancer and Elicits Anti-Tumor Immune Response.
    Cancer Lett. 2019 Aug 29. pii: S0304-3835(19)30450.
    PubMed     Abstract available


  65. QIU N, He YF, Zhang SM, Zhan YT, et al
    Cullin7 Enhances Resistance to Trastuzumab Therapy in Her2 Positive Breast Cancer via Degrading IRS-1 and Downregulating IGFBP-3 to Activate the PI3K/AKT Pathway.
    Cancer Lett. 2019 Aug 25. pii: S0304-3835(19)30439.
    PubMed     Abstract available


    July 2019
  66. KRISHNA BM, Jana S, Singhal J, Horne D, et al
    Notch Signaling in Breast Cancer: From Pathway Analysis to Therapy.
    Cancer Lett. 2019 Jul 18. pii: S0304-3835(19)30408.
    PubMed     Abstract available


    June 2019
  67. WANG HX, Gires O
    Tumor-derived extracellular vesicles in breast cancer: From bench to bedside.
    Cancer Lett. 2019;460:54-64.
    PubMed     Abstract available


    May 2019
  68. FLAHERTY RL, Intabli H, Falcinelli M, Bucca G, et al
    Stress hormone-mediated acceleration of breast cancer metastasis is halted by inhibition of nitric oxide synthase.
    Cancer Lett. 2019 May 24. pii: S0304-3835(19)30322.
    PubMed     Abstract available


  69. LI Y, Acharya G, Elahy M, Xin H, et al
    The Anthelmintic Flubendazole Blocks Human Melanoma Growth and Metastasis and Suppresses Programmed Cell Death Protein-1 and Myeloid-Derived Suppressor Cell Accumulation.
    Cancer Lett. 2019 May 22. pii: S0304-3835(19)30321.
    PubMed     Abstract available


  70. SANTIAGO-GOMEZ A, Kedward T, Simoes BM, Dragoni I, et al
    PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
    Cancer Lett. 2019 May 20. pii: S0304-3835(19)30309.
    PubMed     Abstract available


  71. SUN Q, Wang Y, Desgrosellier JS
    Combined Bcl-2/Src inhibition synergize to deplete stem-like breast cancer cells.
    Cancer Lett. 2019 May 9. pii: S0304-3835(19)30280.
    PubMed     Abstract available


  72. MO D, Jiang P, YiningYang, Mao X, et al
    A tRNA fragment, 5'-tiRNA(Val), suppresses the Wnt/beta-Catenin signaling pathway by targeting FZD3 in breast cancer.
    Cancer Lett. 2019 May 9. pii: S0304-3835(19)30283.
    PubMed     Abstract available


    April 2019
  73. DONG Q, Yang B, Han JG, Zhang MM, et al
    A novel hydrogen sulfide-releasing donor, HA-ADT, suppresses the growth of human breast cancer cells through inhibiting the PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling pathways.
    Cancer Lett. 2019 Apr 28. pii: S0304-3835(19)30268.
    PubMed     Abstract available


  74. WANG H, Yao F, Luo S, Ma K, et al
    A mutual activation loop between the Ca(2+)-activated chloride channel TMEM16A and EGFR/STAT3 signaling promotes breast cancer tumorigenesis.
    Cancer Lett. 2019 Apr 28. pii: S0304-3835(19)30264.
    PubMed     Abstract available


    March 2019
  75. CHEN Y, Sumardika IW, Tomonobu N, Winarsa Ruma IM, et al
    Melanoma cell adhesion molecule is the driving force behind the dissemination of melanoma upon S100A8/A9 binding in the original skin lesion.
    Cancer Lett. 2019 Mar 20. pii: S0304-3835(19)30179.
    PubMed     Abstract available


    February 2019
  76. YANG Y, Wu R, Sargsyan D, Yin R, et al
    UVB drives different stages of epigenome alterations during progression of skin cancer.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30082.
    PubMed     Abstract available


  77. FENG Y, Sessions EH, Zhang F, Ban F, et al
    Identification and characterization of small molecule inhibitors of the ubiquitin ligases Siah1/2 in melanoma and prostate cancer cells.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30084.
    PubMed     Abstract available


  78. AHMED K, Koval A, Xu J, Bodmer A, et al
    Towards the first targeted therapy for triple-negative breast cancer: repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30090.
    PubMed     Abstract available


  79. MARQUEZ-GARBAN DC, Gorrin-Rivas M, Chen HW, Sterling C Jr, et al
    Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression.
    Cancer Lett. 2019 Feb 13. pii: S0304-3835(19)30081.
    PubMed     Abstract available


  80. HE Q, Xue S, Tan Y, Zhang L, et al
    Dual inhibition of Akt and ERK signaling induces cell senescence in triple-negative breast cancer.
    Cancer Lett. 2019 Feb 8. pii: S0304-3835(19)30070.
    PubMed     Abstract available


  81. ZHANG L, Du Y, Xu S, Jiang Y, et al
    DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC.
    Cancer Lett. 2019;442:242-251.
    PubMed     Abstract available


  82. NAMBA M, Hattori N, Hamada H, Yamaguchi K, et al
    Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1.
    Cancer Lett. 2019;442:31-39.
    PubMed     Abstract available


    January 2019
  83. FU S, Chen X, Lo HW, Lin J, et al
    Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer.
    Cancer Lett. 2019 Jan 29. pii: S0304-3835(19)30046.
    PubMed     Abstract available


  84. NEGI H, Merugu SB, Mangukiya HB, Li Z, et al
    Anterior Gradient-2 Monoclonal Antibody Inhibits Lung Cancer Growth and Metastasis by Upregulating p53 Pathway and Without Exerting Any Toxicological Effects: A Preclinical Study.
    Cancer Lett. 2019 Jan 24. pii: S0304-3835(19)30045.
    PubMed     Abstract available


  85. BIANCHINI F, Portioli E, Ferlenghi F, Vacondio F, et al
    Cell-targeted c(AmpRGD)-sunitinib molecular conjugates impair tumor growth of melanoma.
    Cancer Lett. 2019 Jan 10. pii: S0304-3835(19)30012.
    PubMed     Abstract available


  86. VELLANKI SH, Cruz RGB, Jahns H, Hudson L, et al
    Natural compound Tetrocarcin-A downregulates Junctional Adhesion Molecule-A in conjunction with HER2 and inhibitor of apoptosis proteins and inhibits tumor cell growth.
    Cancer Lett. 2019;440-441:23-34.
    PubMed     Abstract available


    December 2018
  87. ZHANG X, Gao D, Fang K, Guo Z, et al
    Med19 is targeted by miR-101-3p/miR-422a and promotes breast cancer progression by regulating the EGFR/MEK/ERK signaling pathway.
    Cancer Lett. 2018 Dec 21. pii: S0304-3835(18)30723.
    PubMed     Abstract available


  88. YUAN G, Lian Z, Liu Q, Lin X, et al
    Phosphatidyl Inositol 3-Kinase (PI3K)-mTOR Inhibitor PKI-402 Inhibits Breast Cancer Induced Osteolysis.
    Cancer Lett. 2018 Dec 9. pii: S0304-3835(18)30704.
    PubMed     Abstract available


    November 2018
  89. ZOU H, Sevigny MB, Liu S, Madden DT, et al
    Novel flexible heteroarotinoid, SL-1-39, inhibits HER2-positive breast cancer cell proliferation by promoting lysosomal degradation of HER2.
    Cancer Lett. 2018 Nov 29. pii: S0304-3835(18)30688.
    PubMed     Abstract available


  90. THAKUR V, Zhang K, Savadelis A, Zmina P, et al
    The membrane tethered matrix metalloproteinase MT1-MMP triggers an outside-in DNA Damage Response that impacts chemo- and radiotherapy responses of breast cancer.
    Cancer Lett. 2018 Nov 28. pii: S0304-3835(18)30697.
    PubMed     Abstract available


  91. BRUMMER C, Faerber S, Bruss C, Blank C, et al
    Metabolic targeting synergizes with MAPK inhibition and delays drug resistance in melanoma.
    Cancer Lett. 2018 Nov 24. pii: S0304-3835(18)30684.
    PubMed     Abstract available


  92. TREMBLE LF, O'Brien MA, Forde PF
    Electrochemotherapy with cisplatin increases survival and induces immunogenic responses in murine models of lung cancer and colorectal cancer.
    Cancer Lett. 2018 Nov 22. pii: S0304-3835(18)30680.
    PubMed     Abstract available


  93. FURST K, Steder M, Logotheti S, Angerilli A, et al
    DNp73-induced degradation of tyrosinase links depigmentation with EMT-driven melanoma progression.
    Cancer Lett. 2018;442:299-309.
    PubMed     Abstract available


  94. YU L, Wang L, Mao C, Duraki D, et al
    Estrogen-Independent Myc Overexpression Confers Endocrine Therapy Resistance on Breast Cancer Cells Expressing ERalphaY537S and ERalphaD538G Mutations.
    Cancer Lett. 2018 Nov 9. pii: S0304-3835(18)30662.
    PubMed     Abstract available


  95. WANG X, Qi Y, Kong X, Zhai J, et al
    Recent Advances in the Research of Immunotherapy for Triple-Negative Breast Cancer.
    Cancer Lett. 2018 Nov 9. pii: S0304-3835(18)30664.
    PubMed     Abstract available


    October 2018
  96. CHIU CS, Tsai CH, Hsieh MS, Tsai SC, et al
    Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and beta-catenin pathways.
    Cancer Lett. 2018 Oct 31. pii: S0304-3835(18)30640.
    PubMed     Abstract available


  97. SUN HF, Yang XL, Zhao Y, Tian Q, et al
    Loss of TMEM126A promotes extracellular matrix remodeling, epithelial-to-mesenchymal transition, and breast cancer metastasis by regulating mitochondrial retrograde signaling.
    Cancer Lett. 2018;440-441:189-201.
    PubMed     Abstract available


  98. WEN S, Hou Y, Fu L, Xi L, et al
    Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin beta3-p38 MAPK signalling.
    Cancer Lett. 2018 Oct 26. pii: S0304-3835(18)30629.
    PubMed     Abstract available


  99. GUPTA P, Gupta N, Fofaria NM, Ranjan A, et al
    HER2-mediated GLI2 stabilization promotes anoikis resistance and metastasis of breast cancer cells.
    Cancer Lett. 2018;442:68-81.
    PubMed     Abstract available


  100. XIAO YS, Zeng, Liang YK, Wu Y, et al
    Major vault protein is a direct target of Notch1 signaling and contributes to chemoresistance in triple-negative breast cancer cells.
    Cancer Lett. 2018 Oct 15. pii: S0304-3835(18)30608.
    PubMed     Abstract available


  101. DING J, Wang X, Zhang Y, Sang X, et al
    Inhibition of BTF3 sensitizes luminal breast cancer cells to PI3Kalpha inhibition through the transcriptional regulation of ERalpha.
    Cancer Lett. 2018 Oct 10. pii: S0304-3835(18)30605.
    PubMed     Abstract available


    September 2018
  102. SATHYANARAYANA UG, Moore AY, Li L, Padar A, et al
    Retraction notice to "Sun exposure related methylation in malignant and non-malignant skin lesions" [Cancer Letters 245/1-2 (2007) 112-120].
    Cancer Lett. 2018;432:272.
    PubMed    


  103. SEIP K, Jorgensen K, Haselager MV, Albrecht M, et al
    "Stroma-induced phenotypic plasticity offers phenotype-specific targeting to improve melanoma treatment".
    Cancer Lett. 2018 Sep 18. pii: S0304-3835(18)30580.
    PubMed     Abstract available


  104. ZHANG C, Zhang M, Song S
    Cathepsin D enhances breast cancer invasion and metastasis through promoting hepsin ubiquitin-proteasome degradation.
    Cancer Lett. 2018 Sep 15. pii: S0304-3835(18)30576.
    PubMed     Abstract available


  105. LIN CC, Lo MC, Moody R, Jiang H, et al
    Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer.
    Cancer Lett. 2018 Sep 15. pii: S0304-3835(18)30577.
    PubMed     Abstract available


    August 2018
  106. BARONE I, Vircillo V, Giordano C, Gelsomino L, et al
    Activation of Farnesoid X Receptor Impairs The Tumor-Promoting Function of Breast Cancer-Associated Fibroblasts.
    Cancer Lett. 2018 Aug 31. pii: S0304-3835(18)30544.
    PubMed     Abstract available


  107. WU Q, Chen D, Luo Q, Yang Q, et al
    Extracellular matrix protein 1 recruits moesin to facilitate invadopodia formation and breast cancer metastasis.
    Cancer Lett. 2018 Aug 27. pii: S0304-3835(18)30540.
    PubMed     Abstract available


  108. ZHANG H, Zhang Y, Chen C, Zhu X, et al
    A double-negative feedback loop between DEAD-box protein DDX21 and Snail regulates epithelial-mesenchymal transition and metastasis in breast cancer.
    Cancer Lett. 2018 Aug 27. pii: S0304-3835(18)30539.
    PubMed     Abstract available


  109. LOPES R, Korkmaz G, Revilla SA, van Vliet R, et al
    CUEDC1 is a primary target of ERalpha essential for the growth of breast cancer cells.
    Cancer Lett. 2018;436:87-95.
    PubMed     Abstract available


    July 2018
  110. DYCZYNSKI M, Yu Y, Otrocka M, Parpal S, et al
    Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.
    Cancer Lett. 2018 Jul 25. pii: S0304-3835(18)30486.
    PubMed     Abstract available


  111. NIKAS I, Ryu HS, Theocharis S
    Viewing the Eph receptors with a focus on breast cancer heterogeneity.
    Cancer Lett. 2018;434:160-171.
    PubMed     Abstract available


  112. FAN TC, Yeo HL, Hsu HM, Yu JC, et al
    Reciprocal feedback regulation of ST3GAL1 and GFRA1 signaling in breast cancer cells.
    Cancer Lett. 2018 Jul 21. pii: S0304-3835(18)30484.
    PubMed     Abstract available


  113. QIU H, Zmina PM, Huang AY, Askew D, et al
    Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.
    Cancer Lett. 2018 Jul 20. pii: S0304-3835(18)30482.
    PubMed     Abstract available


  114. CHEN X, Liu P, Wang Q, Li Y, et al
    DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
    Cancer Lett. 2018 Jul 11. pii: S0304-3835(18)30470.
    PubMed     Abstract available


  115. LIU XL, Xu YC, Wang YX, Chen Y, et al
    Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kalpha-selective inhibitor CYH33 in breast cancer.
    Cancer Lett. 2018 Jul 9. pii: S0304-3835(18)30469.
    PubMed     Abstract available


  116. LEE YS, Jung YY, Park MH, Yeo IJ, et al
    Deficiency of parkin suppresses melanoma tumor development and metastasis through inhibition of MFN2 ubiquitination.
    Cancer Lett. 2018;433:156-164.
    PubMed     Abstract available


    June 2018
  117. GU J, Wang Y, Wang X, Zhou D, et al
    Downregulation of lncRNA GAS5 confers tamoxifen resistance by activating miR-222 in breast cancer.
    Cancer Lett. 2018 Jun 30. pii: S0304-3835(18)30447.
    PubMed     Abstract available


  118. XIAO Y, Li Y, Tao H, Humphries B, et al
    Integrin alpha5 down-regulation by miR-205 suppresses triple negative breast cancer stemness and metastasis by inhibiting the Src/Vav2/Rac1 pathway.
    Cancer Lett. 2018 Jun 29. pii: S0304-3835(18)30445.
    PubMed     Abstract available


  119. SALINAS-VERA YM, Marchat LA, Garcia-Vazquez R, Gonzalez de la Rosa CH, et al
    Cooperative multi-targeting of signaling networks by angiomiR-204 inhibits vasculogenic mimicry in breast cancer cells.
    Cancer Lett. 2018;432:17-27.
    PubMed     Abstract available


  120. SAUVAGE F, Fattal E, Al-Shaer W, Denis S, et al
    Antitumor activity of nanoliposomes encapsulating the novobiocin analogue 6BrCaQ in a triple-negative breast cancer model in mice.
    Cancer Lett. 2018 Jun 5. pii: S0304-3835(18)30397.
    PubMed     Abstract available


    May 2018
  121. MEHTA PP, Kung PP, Yamazaki S, Walls M, et al
    Retraction notice to "A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells".
    Cancer Lett. 2018;422:132.
    PubMed    


  122. ZHENG Y, Wang K, Wu Y, Chen Y, et al
    Pinocembrin induces ER stress mediated apoptosis and suppresses autophagy in melanoma cells.
    Cancer Lett. 2018;431:31-42.
    PubMed     Abstract available


  123. WU J, Jiang Z, Chen C, Hu Q, et al
    CircIRAK3 sponges miR-3607 to facilitate breast cancer metastasis.
    Cancer Lett. 2018;430:179-192.
    PubMed     Abstract available


  124. LI Y, Huang J, Zeng B, Yang D, et al
    PSMD2 regulates breast cancer cell proliferation and cell cycle progression by modulating p21 and p27 proteasomal degradation.
    Cancer Lett. 2018 May 16. pii: S0304-3835(18)30343.
    PubMed     Abstract available


  125. LIU Y, Geng YH, Yang H, Yang H, et al
    Extracellular ATP drives breast cancer cell migration and metastasis via S100A4 production by cancer cells and fibroblasts.
    Cancer Lett. 2018 May 4. pii: S0304-3835(18)30318.
    PubMed     Abstract available


    April 2018
  126. GELSOMINO L, Panza S, Giordano C, Barone I, et al
    Mutations in the Estrogen Receptor Alpha Hormone Binding Domain Promote Stem Cell Phenotype through Notch Activation in Breast Cancer Cell Lines.
    Cancer Lett. 2018 Apr 24. pii: S0304-3835(18)30290.
    PubMed     Abstract available


  127. OJO D, Lin X, Wu Y, Cockburn J, et al
    Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
    Cancer Lett. 2018;426:4-13.
    PubMed     Abstract available


    March 2018
  128. ZANOTTO-FILHO A, Rajamanickam S, Loranc E, Masamsetti P, et al
    Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells.
    Cancer Lett. 2018 Mar 30. pii: S0304-3835(18)30240.
    PubMed     Abstract available


  129. CHO HJ, Kim JT, Lee SJ, Hwang YS, et al
    Protein phosphatase 1B dephosphorylates Rho guanine nucleotide dissociation inhibitor 1 and suppresses cancer cell migration and invasion.
    Cancer Lett. 2018;417:141-151.
    PubMed     Abstract available


  130. VAN HEETVELDE M, Van Bockstal M, Poppe B, Lambein K, et al
    Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2-associated hereditary breast and ovarian cancer reveals multiple co-acting second hits.
    Cancer Lett. 2018 Mar 23. pii: S0304-3835(18)30223.
    PubMed     Abstract available


  131. LAWSON JS, Salmons B, Gunzburg WH
    Commentary regarding Gannon et al. "Viral infections and breast cancer - A current perspective".
    Cancer Lett. 2018;424:117-118.
    PubMed    


  132. LI D, Wang H, Ding Y, Zhang Z, et al
    Targeting the NRF-2/RHOA/ROCK signaling pathway with a novel aziridonin, YD0514, to suppress breast cancer progression and lung metastasis.
    Cancer Lett. 2018;424:97-108.
    PubMed     Abstract available


  133. MARSAVELA G, Aya-Bonilla CA, Warkiani ME, Gray ES, et al
    Melanoma circulating tumor cells: Benefits and challenges required for clinical application.
    Cancer Lett. 2018;424:1-8.
    PubMed     Abstract available


  134. SUH J, Kim DH, Kim EH, Park SA, et al
    15-Deoxy-Delta(12,14)-prostaglandin J2 activates PI3K-Akt signaling in human breast cancer cells through covalent modification of the tumor suppressor PTEN at cysteine 136.
    Cancer Lett. 2018 Mar 14. pii: S0304-3835(18)30207.
    PubMed     Abstract available


  135. FERNANDEZ-NOGUEIRA P, Noguera-Castells A, Fuster G, Recalde-Percaz L, et al
    Histamine receptor 1 inhibition enhances antitumor therapeutic responses through extracellular signal-regulated kinase (ERK) activation in breast cancer.
    Cancer Lett. 2018 Mar 13. pii: S0304-3835(18)30205.
    PubMed     Abstract available


  136. TANG J, Zhou H, Hou X, Wang L, et al
    Enhanced anti-tumor efficacy of temozolomide-loaded carboxylated poly(amido-amine) combined with photothermal/photodynamic therapy for melanoma treatment.
    Cancer Lett. 2018;423:16-26.
    PubMed     Abstract available


    February 2018
  137. HU Y, Yague E, Zhao J, Wang L, et al
    Sabutoclax, pan-active BCL-2 protein family antagonist, overcomes drug resistance and eliminates cancer stem cells in breast cancer.
    Cancer Lett. 2018 Feb 26. pii: S0304-3835(18)30177.
    PubMed     Abstract available


    January 2018
  138. MO D, Zhao Y, Balajee AS
    Human RecQL4 helicase plays multifaceted roles in the genomic stability of normal and cancer cells.
    Cancer Lett. 2018;413:1-10.
    PubMed     Abstract available


  139. MIRZAEI H, Salehi H, Oskuee RK, Mohammadpour A, et al
    The therapeutic potential of human adipose-derived mesenchymal stem cells producing CXCL10 in a mouse melanoma lung metastasis model.
    Cancer Lett. 2018 Jan 10. pii: S0304-3835(18)30051.
    PubMed     Abstract available


  140. DI GENNARO P, Gerlini G, Caporale R, Sestini S, et al
    T regulatory cells mediate immunosuppresion by adenosine in peripheral blood, sentinel lymph node and TILs from melanoma patients.
    Cancer Lett. 2018 Jan 3. pii: S0304-3835(18)30005.
    PubMed     Abstract available


    December 2017
  141. PLATONOV ME, Borovjagin AV, Kaverina N, Xiao T, et al
    KISS1 tumor suppressor restricts angiogenesis of breast cancer brain metastases and sensitizes them to oncolytic virotherapy in vitro.
    Cancer Lett. 2017 Dec 18. pii: S0304-3835(17)30796.
    PubMed     Abstract available


  142. KIM HY, Ha Thi HT, Hong S
    IMP2 and IMP3 cooperate to promote the metastasis of triple-negative breast cancer through destabilization of progesterone receptor.
    Cancer Lett. 2017;415:30-39.
    PubMed     Abstract available


    November 2017
  143. RODRIGUEZ CI, Castro-Perez E, Longley BJ, Setaluri V, et al
    Elevated cyclic AMP levels promote BRAF(CA)/Pten(-/-) mouse melanoma growth but pCREB is negatively correlated with human melanoma progression.
    Cancer Lett. 2017 Nov 24. pii: S0304-3835(17)30749.
    PubMed     Abstract available


  144. CAI X, Wang X, Cao C, Gao Y, et al
    HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
    Cancer Lett. 2017 Nov 21. pii: S0304-3835(17)30740.
    PubMed     Abstract available


  145. KIM YJ, Sung D, Oh E, Cho Y, et al
    Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer.
    Cancer Lett. 2017;412:118-130.
    PubMed     Abstract available


    October 2017
  146. BAI XY, Li S, Wang M, Li X, et al
    Kruppel-like factor 9 down-regulates matrix metalloproteinase 9 transcription and suppresses human breast cancer invasion.
    Cancer Lett. 2017;412:224-235.
    PubMed     Abstract available


  147. SYNNOTT NC, Bauer MR, Madden S, Murray A, et al
    Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007.
    Cancer Lett. 2017 Oct 22. pii: S0304-3835(17)30622.
    PubMed     Abstract available


  148. WILMANSKI T, Zhou X, Zheng W, Shinde A, et al
    Inhibition of Pyruvate Carboxylase by 1alpha,25-Dihydroxyvitamin D Promotes Oxidative Stress in Early Breast Cancer Progression.
    Cancer Lett. 2017 Oct 9. pii: S0304-3835(17)30606.
    PubMed     Abstract available


  149. SOHN EJ, Jung DB, Lee H, Han I, et al
    CNOT2 promotes proliferation and angiogenesis via VEGF signaling in MDA-MB-231 breast cancer cells.
    Cancer Lett. 2017 Oct 9. pii: S0304-3835(17)30621.
    PubMed     Abstract available


  150. FIGUEIRA MI, Cardoso HJ, Correia S, Maia CJ, et al
    The stem cell factor (SCF)/c-KIT system in carcinogenesis of reproductive tissues: What does the hormonal regulation tell us?
    Cancer Lett. 2017;405:10-21.
    PubMed     Abstract available


    September 2017
  151. MARINO S, Bishop RT, Logan JG, Mollat P, et al
    Pharmacological evidence for the bone-autonomous contribution of the NFkappaB/beta-catenin axis to breast cancer related osteolysis.
    Cancer Lett. 2017 Sep 28. pii: S0304-3835(17)30587.
    PubMed     Abstract available


  152. OLADAPO HO, Tarpley M, Sauer SJ, Addo KA, et al
    Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells.
    Cancer Lett. 2017 Sep 28. pii: S0304-3835(17)30586.
    PubMed     Abstract available


  153. XU H, Lin F, Wang Z, Yang L, et al
    CXCR2 Promotes Breast Cancer Metastasis and Chemoresistance via suppression of AKT1 and activation of COX2.
    Cancer Lett. 2017 Sep 27. pii: S0304-3835(17)30583.
    PubMed     Abstract available


  154. AL-MATOUQ J, Holmes T, Hammiller B, Tran N, et al
    Accumulation of cytoplasmic CDC25A in cutaneous squamous cell carcinoma leads to a dependency on CDC25A for cancer cell survival and tumor growth.
    Cancer Lett. 2017 Sep 23. pii: S0304-3835(17)30573.
    PubMed     Abstract available


  155. AIDA S, Sonobe Y, Tanimura H, Oikawa N, et al
    MITF suppression improves the sensitivity of melanoma cells to a BRAF inhibitor.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30555.
    PubMed     Abstract available


  156. HUANG GX, Wang Y, Su J, Zhou P, et al
    Up-regulation of Rho-associated kinase 1/2 by glucocorticoids promotes migration, invasion and metastasis of melanoma.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30552.
    PubMed     Abstract available


  157. WANG S, Zhou R, Sun F, Li R, et al
    The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models.
    Cancer Lett. 2017 Sep 15. pii: S0304-3835(17)30551.
    PubMed     Abstract available


    August 2017
  158. QIN H, Liu X, Li F, Miao L, et al
    PAD1 promotes epithelial-mesenchymal transition and metastasis in triple-negative breast cancer cells by regulating MEK1-ERK1/2-MMP2 signaling.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30506.
    PubMed     Abstract available


  159. WANG B, Zhao H, Zhao L, Zhang Y, et al
    Up-regulation of OLR1 expression by TBC1D3 through activation of TNFalpha/NF-kappaB pathway promotes the migration of human breast cancer cells.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30508.
    PubMed     Abstract available


  160. FALLATAH M, Liu S, Sevigny MB, Zou H, et al
    Novel flexible heteroarotinoid, SL-1-18, promotes ERalpha degradation to inhibit breast cancer cell growth.
    Cancer Lett. 2017 Aug 24. pii: S0304-3835(17)30513.
    PubMed     Abstract available


  161. AMUNJELA JN, Tucker SJ
    POPDC1 is suppressed in human breast cancer tissues and is negatively regulated by EGFR in breast cancer cell lines.
    Cancer Lett. 2017;406:81-92.
    PubMed     Abstract available


    June 2017
  162. HALLDORSSON S, Rohatgi N, Magnusdottir M, Choudhary KS, et al
    Metabolic re-wiring of isogenic breast epithelial cell lines following epithelial to mesenchymal transition.
    Cancer Lett. 2017;396:117-129.
    PubMed     Abstract available


    May 2017
  163. YU ZH, Lun SM, He R, Tian HP, et al
    The dual function of MAZ mediated by FOXF2 in basal-like breast cancer: Suppression of progression but promotion of proliferation.
    Cancer Lett. 2017 May 31. pii: S0304-3835(17)30356.
    PubMed     Abstract available


    March 2017
  164. DESHMUKH SK, Srivastava SK, Zubair H, Bhardwaj A, et al
    Resistin potentiates chemoresistance and stemness of breast cancer cells: implications for racially disparate therapeutic outcomes.
    Cancer Lett. 2017 Mar 13. pii: S0304-3835(17)30174.
    PubMed     Abstract available


  165. MONTEIRO FL, Vitorino R, Wang J, Cardoso H, et al
    The histone H2A isoform Hist2h2ac is a novel regulator of proliferation and epithelial-mesenchymal transition in mammary epithelial and in breast cancer cells.
    Cancer Lett. 2017 Mar 10. pii: S0304-3835(17)30171.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Dermatology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: